July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Anti-inflammatory and anti-angiogenic effects of an expoxidation-resistant expoxyeicosatetraenoic acid analog in choroidal neovascularization
Author Affiliations & Notes
  • Elizabeth Pearsall
    Ophthalmology, Massachusetts Eye & Ear , Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Eiichi Hasegawa
    Ophthalmology, Massachusetts Eye & Ear , Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Saori Inafuku
    Ophthalmology, Massachusetts Eye & Ear , Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Yoko Okunuki
    Ophthalmology, Massachusetts Eye & Ear , Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • John R Falck
    Biochemistry, University of Texas Southwestern Medical Center, Dallas, Texas, United States
  • Kip M Connor
    Ophthalmology, Massachusetts Eye & Ear , Boston, Massachusetts, United States
    Ophthalmology, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Elizabeth Pearsall, None; Eiichi Hasegawa, None; Saori Inafuku, None; Yoko Okunuki, None; John Falck, University of Texas Southwestern (P); Kip Connor, None
  • Footnotes
    Support  National Eye Institute grant 1R01EY027303 , the Bright Focus Foundation, and the Massachusetts Lions Fund (K.M.C.).
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1649. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Elizabeth Pearsall, Eiichi Hasegawa, Saori Inafuku, Yoko Okunuki, John R Falck, Kip M Connor; Anti-inflammatory and anti-angiogenic effects of an expoxidation-resistant expoxyeicosatetraenoic acid analog in choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1649.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Metabolites of long-chain polyunsaturated fatty acids generated by the cytochrome P450 (CYP) pathway have potent anti-angiogenic effects in neovascular eye disease. Specifically, epoxyeicosatetraenoic acids (EEQs) alleviate choroidal neovascularization (CNV) by suppressing inflammation. However, EEQs are rapidly broken down by the soluble epoxide hydrolase (sEH), and sEH products are pro-inflammatory. We therefore generated an analog of 17,18-EEQ, known as C21, which lacks an expoxidation site and therefore cannot be broken down by sEH. In the present study, we assessed anti-angiogenic and anti-inflammatory effects of C21 in laser-induced CNV, and identified novel systemic immunomodulatory effects.

Methods : CNV was induced by laser photocoagulation in C57BL/6J mice, and C21 was administered intraperitoneally (i.p., 50 mg/kg/day) immediately after photocoagulation and daily thereafter. At day 7, CNV lesion size, lesion edema, vascular leakage, and immune cell recruitment were measured. Serum concentrations of C21 were measured to determine serum half-life of C21 in mice receiving i.p. injection. To determine if the protective effects of C21 were systemic or local, peritoneal cells of donor mice receiving vehicle or C21 were transferred to untreated recipient mice, and CNV disease severity was assessed in recipient mice.

Results : C21 administration significantly decreased CNV disease severity, decreasing neovascular lesion size, lesion edema, and lesion vascular leakage. Further, C21 decreased immune cell recruitment to CNV lesions. Pharmacokinetic studies demonstrated a relatively short serum half-life of C21 in mice receiving i.p. injections, prompting us to investigate whether the effects of C21 were localized to the retina, or rather were systemic, modulating immune cell differentiation and/or activation. Interestingly, adoptive transfer of peritoneal cells from C21-treated donor mice to naïve recipient mice decreased CNV disease severity in recipient mice, suggesting C21 plays a systemic role in CNV resolution that may be due in part to immunomodulation.

Conclusions : Together, these data demonstrate that EEQs modulate immune cell recruitment to CNV lesions, suppressing inflammation and subsequent neovascularization. C21, which is resistant to breakdown by sEH, may be a particularly effective therapeutic modality for neovascular AMD.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×